Halozyme to license drug delivery tech to Roche, Bristol-Myers

(Reuters) - U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations.